Mostrando postagens com marcador Bipolar disease. Mostrar todas as postagens
Mostrando postagens com marcador Bipolar disease. Mostrar todas as postagens

sexta-feira, 24 de outubro de 2014

Bipolar disorder discovery at the nano level

 


A nano-sized discovery by Northwestern Medicine® scientists helps explain how bipolar disorder affects the brain and could one day lead to new drug therapies to treat the mental illness.

Scientists used a new super-resolution imaging method -- the same method recognized with the 2014 Nobel Prize in chemistry -- to peer deep into brain tissue from mice with bipolar-like behaviors. In the synapses (where communication between brain cells occurs), they discovered tiny "nanodomain" structures with concentrated levels of ANK3 -- the gene most strongly associated with bipolar disorder risk. ANK3 is coding for the protein ankyrin-G.

"We knew that ankyrin-G played an important role in bipolar disease, but we didn't know how," said Northwestern Medicine scientist Peter Penzes, corresponding author of the paper. "Through this imaging method we found the gene formed in nanodomain structures in the synapses, and we determined that these structures control or regulate the behavior of synapses."

Penzes is a professor in physiology and psychiatry and behavioral sciences at Northwestern University Feinberg School of Medicine. The results were published Oct. 22 in the journal Neuron.

High-profile cases, including actress Catherine Zeta-Jones and politician Jesse Jackson, Jr., have brought attention to bipolar disorder. The illness causes unusual shifts in mood, energy, activity levels and the ability to carry out day-to-day tasks. About 3 percent of Americans experience bipolar disorder symptoms, and there is no cure.

Recent large-scale human genetic studies have shown that genes can contribute to disease risk along with stress and other environmental factors. However, how these risk genes affect the brain is not known.

This is the first time any psychiatric risk gene has been analyzed at such a detailed level of resolution. As explained in the paper, Penzes used the Nikon Structured Illumination Super-resolution Microscope to study a mouse model of bipolar disorder. The microscope realizes resolution of up to 115 nanometers. To put that size in perspective, a nanometer is one-tenth of a micron, and there are 25,400 microns in one inch. Very few of these microscopes exist worldwide.

"There is important information about genes and diseases that can only been seen at this level of resolution," Penzes said. "We provide a neurobiological explanation of the function of the leading risk gene, and this might provide insight into the abnormalities in bipolar disorder."

The biological framework presented in this paper could be used in human studies of bipolar disorder in the future, with the goal of developing therapeutic approaches to target these genes.


Story Source:

The above story is based on materials provided by Northwestern University. The original article was written by Erin White. Note: Materials may be edited for content and length.


Journal Reference:

  1. Katharine R. Smith, Katherine J. Kopeikina, Jessica M. Fawcett-Patel, Katherine Leaderbrand, Ruoqi Gao, Britta Schürmann, Kristoffer Myczek, Jelena Radulovic, Geoffrey T. Swanson, Peter Penzes. Psychiatric Risk Factor ANK3/Ankyrin-G Nanodomains Regulate the Structure and Function of Glutamatergic Synapses. Neuron, 2014; 84 (2): 399 DOI: 10.1016/j.neuron.2014.10.010

:

sexta-feira, 23 de maio de 2014

Bipolar disease in children, adolescents: Discharge rates much higher in the US compared to UK

 

A study published in the June 2014 issue of the Journal of the American Academy of Child and Adolescent Psychiatry found a very much higher discharge rate for pediatric bipolar (PBD) in children and adolescents aged 1-19 years in the US compared to England between the years 2000-2010.

Using the English NHS Hospital Episode Statistics (HES) dataset and the US National Hospital Discharge Survey (NHDS) to compare US and English discharge rates for PBD over the period 2000-2010, the authors found a 72.1-fold higher discharge rate for pediatric bipolar in youth in the US compared to England. After controlling for cross-national differences in length of stay, discharge rates for PBD remained 12.5 times higher in the US than in England, and for all other child psychiatric diagnoses the discharge rate was 3.9 higher, and for adults with BD 7.2 fold higher, in the US than in England.

Dr. Anthony James, with the University of Oxford, and lead author of the paper, said of the study, "The finding that the disparity between US and English discharge rates for PBD is markedly greater than the disparity for child psychiatric discharge rates overall, and for adult rates for bipolar disorder, is potentially important. However, the study design does not allow us to answer the question whether US clinicians are too liberal in assigning the diagnosis of bipolar disorder to youth or, alternatively, whether English clinicians fail to recognize or diagnose these illnesses. It is clear that the reasons for the disparity in the case of PBD warrant further study." 


Story Source:

The above story is based on materials provided by Elsevier. Note: Materials may be edited for content and length.


Journal References:

  1. Anthony James, Uy Hoang, Valerie Seagroatt, Joe Clacey, Michael Goldacre, Ellen Leibenluft. A Comparison of American and English Hospital Discharge Rates for Pediatric Bipolar Disorder, 2000 to 2010. Journal of the American Academy of Child & Adolescent Psychiatry, 2014; 53 (6): 614 DOI: 10.1016/j.jaac.2014.02.008
  2. Argyris Stringaris, Eric Youngstrom. Unpacking the Differences in US/UK Rates of Clinical Diagnoses of Early-Onset Bipolar Disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 2014; 53 (6): 609 DOI: 10.1016/j.jaac.2014.02.013